<SEC-DOCUMENT>0001193125-23-257049.txt : 20231017
<SEC-HEADER>0001193125-23-257049.hdr.sgml : 20231017
<ACCEPTANCE-DATETIME>20231016192355
ACCESSION NUMBER:		0001193125-23-257049
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20231016
FILED AS OF DATE:		20231017
DATE AS OF CHANGE:		20231016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		231328241

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d761709d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated October&nbsp;16, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d761709dex991.htm">Immutep Announces Publication of Abstracts at ESMO Congress 2023 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October&nbsp;16, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d761709dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g761709g43r12.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g761709g99m68.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Publication of Abstracts at ESMO Congress 2023 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>New updated data from <FONT STYLE="white-space:nowrap">TACTI-002,</FONT> including more mature Overall
Survival data, will be presented during the Mini Oral session on Saturday, October 21st, at 9:05 CEST</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Immutep to host webcast to discuss ESMO 2023 clinical data on Monday, October 23rd, at 8AM AEDT (Sunday,
October 22nd, at 5PM ET)</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 16</B><B></B><B>&nbsp;October </B><B>2023 &#150;</B> <U>Immutep Limited</U>
(ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces the
publication of abstracts with data from the <FONT STYLE="white-space:nowrap">TACTI-002</FONT> and <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> trials in 1st line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (1L NSCLC) at
the 2023 European Society for Medical Oncology (ESMO) Congress. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-002</FONT> is a Phase II trial evaluating the
chemotherapy-free combination of eftilagimod alpha (&#147;efti&#148;) and KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab), MSD&#146;s (Merck&nbsp;&amp; Co., Rahway, NJ, USA) <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, in 1L NSCLC. The <FONT STYLE="white-space:nowrap">TACTI-002</FONT> abstract published by ESMO, which contains data based on a <FONT STYLE="white-space:nowrap">cut-off</FONT> date of
31&nbsp;March 2023, showed an excellent initial survival benefit across an <FONT STYLE="white-space:nowrap">all-comer</FONT> <FONT STYLE="white-space:nowrap">PD-L1</FONT> patient population in 1L NSCLC as well as for patients in each <FONT
STYLE="white-space:nowrap">PD-L1</FONT> Tumour Proportion Score (TPS) subgroup, including 38.8 months in TPS <U>&gt;</U>50%, 23.4 months in TPS <FONT STYLE="white-space:nowrap">1-49%,</FONT> and 25.0 months in TPS <U>&gt;</U>1% <I>(the OS result in
TPS </I><I><U>&gt;</U></I><I>1%, a key area of focus for future development where efti has FDA Fast Track designation, </I><I><U>was already reported on May&nbsp;17, 2023).</U></I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notably, new updated data from <FONT STYLE="white-space:nowrap">TACTI-002,</FONT> including more mature Overall Survival (OS) results, will be presented by
Dr.&nbsp;Enric Carcereny, Catalan Institute of Oncology, Badalona (ICO), during a Mini Oral session (#1312MO) at ESMO Congress 2023 on Saturday, October&nbsp;21, 2023, at 9:05 AM CEST. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> is an investigator-initiated Phase I trial conducted by the Frankfurt Institute of Clinical Cancer
Research IKF evaluating efti in conjunction with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and doublet chemotherapy in <FONT STYLE="white-space:nowrap">non-squamous</FONT> 1L NSCLC patients. The data in the <FONT
STYLE="white-space:nowrap">INSIGHT-003</FONT> abstract, with a <FONT STYLE="white-space:nowrap">cut-off</FONT> date of 18&nbsp;April 2023, showed a promising 67% overall response rate. Additionally, a Trials in Progress (TiP) abstract on the <FONT
STYLE="white-space:nowrap">EFTISARC-NEO</FONT> trial evaluating efti in combination with radiotherapy and KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> titled has been published. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abstracts&nbsp;are available on the&nbsp;ESMO&nbsp;<U>website</U>, and the mini oral presentation&nbsp;&amp; posters will be available on Immutep&#146;s
website following their presentation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Presentation Details</U>: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: <I>Combining the antigen-presenting cell activator eftilagimod alpha (soluble <FONT STYLE="white-space:nowrap">LAG-3)</FONT> and pembrolizumab: overall
survival data from the 1</I><I><SUP STYLE="font-size:75%; vertical-align:top">st</SUP></I><I> line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung carcinoma (NSCLC) cohort of <FONT STYLE="white-space:nowrap">TACTI-002</FONT> (Phase
II)</I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Presenter: Dr.&nbsp;Enric Carcereny, Catalan Institute of Oncology, Badalona (ICO) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date and Time: Saturday, October&nbsp;21, 2023; 9:10 AM CEST </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mini Oral session &#150; NSCLC, metastatic </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Presentation # <U>1312MO</U> </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g761709g43r12.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g761709g99m68.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: <I><FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> evaluating feasibility of eftilagimod alpha
(soluble <FONT STYLE="white-space:nowrap">LAG-3)</FONT> combined with 1</I><I><SUP STYLE="font-size:75%; vertical-align:top">st</SUP></I><I> line chemo-immunotherapy in metastatic <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer
(NSCLC) adenocarcinomas</I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Speaker: Dr.&nbsp;Akin Atmaca, Krankenhaus Nordwest (IKF) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date: Monday, October&nbsp;23, 2023 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Poster presentation, # <U>1042P</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: <I>Pembrolizumab in combination with eftilagimod alpha and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas &#150; <FONT
STYLE="white-space:nowrap">EFTISARC-NEO</FONT> trial</I> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Speaker: Dr.&nbsp;Katarzyna Kozak, Maria Sk&#322;odowska-Curie National Research Institute of Oncology
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Date: Monday, October&nbsp;23, 2023 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Poster presentation, # <U>1987TiP</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Conference Call and Webcast</U>: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep will host a
conference call and webcast to discuss the clinical data presented at ESMO 2023 and provide an overview on future clinical development plans for efti in 1st line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer. The event will
feature Immutep CEO Marc Voigt, CSO Dr Frederic Triebel, CMO Dr Florian Vogl, and Christian Mueller, Senior Vice President Strategic Development. An open question&nbsp;&amp; answer session with all presenters will conclude the event. A replay of the
webcast will be available under the Events section of Immutep&#146;s website. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Date/Time</U>: Monday, October 23rd, at 8AM AEDT (Sunday, October 22nd, at 5PM ET) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Register</U>: Link to register <U>here</U>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U>Questions:</U> Investors are invited to submit questions in advance via<U> immutep@citadelmagnus.com</U>.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a
subsidiary of Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and
adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex)
Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT
STYLE="white-space:nowrap">IFN-&#436;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for
a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations,
including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States
Food and Drug Administration (FDA). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g761709g43r12.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g761709g99m68.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune
disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio
harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information,
please visit <U>www.immutep.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the Board of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g761709g43r12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g761709g43r12.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M=P9E12S$!1U)[4#$21)%#(P93T(.0: '4 % !0 4 % !0 4 % !0 4 % !0
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MMU#N;C_CUEQ_</\ *MV=S^$XKP7#)'JTQ>-E'DGDC'<5C25F<6&34W<A\?\
MAZZN+N/5+.%I0$VRJ@RPQT/^?2MSO*=M\1[^WMD@N+&.65!MWEBI/U'K0!!X
M"MKD^)A=-;RB$H^7V':">V: -7XA:'=74T&HVL+2JD>R0(,E0#D''XF@"C9_
M$34(;2.U-@DTZJ%#[CDX]5]: .NU/3F\3^%8TE3R;EXUE4,I&Q\=,=<=1^-
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MNX6AE$K':W7'% '24 % !0 4 % !0 8H ,"@ H ,4 % !B@ H * "@ Q0 4
=% !0 8H ,4 % !B@ H * "@ H * "@ H * /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g761709g99m68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g761709g99m68.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_"&:7ZS?]]__ %J/91#ZM /^$,TOUF_[[_\ K4>RB'U: ?\ "&:7ZS?]]_\
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M ?\ "&:7ZS?]]_\ UJ/91#ZM /\ A#-+]9O^^_\ ZU'LHA]6@'_"&:7ZS?\
M??\ ]:CV40^K0#_A#-+]9O\ OO\ ^M1[*(?5H!_PAFE^LW_??_UJ/91#ZM /
M^$,TOUF_[[_^M1[*(?5H!_PAFE^LW_??_P!:CV40^K0#_A#-+]9O^^__ *U'
MLHA]6@'_  AFE^LW_??_ -:CV40^K0#_ (0S2_6;_OO_ .M1[*(?5H!_PAFE
M^LW_ 'W_ /6H]E$/JT _X0S2_6;_ +[_ /K4>RB'U: ?\(9I?K-_WW_]:CV4
M0^K0#_A#-+]9O^^__K4>RB'U: ?\(9I?K-_WW_\ 6H]E$/JT _X0S2_6;_OO
M_P"M1[*(?5H!_P (9I?K-_WW_P#6H]E$/JT _P"$,TOUF_[[_P#K4>RB'U:
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7$/JT _X0S2_6;_OO_P"M3]F@^K0/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
